Will the NHS Prescribe Mounjaro — and Do You Qualify?

The misconception: 'NICE approved it, so my GP can prescribe it now'

This is the most common misunderstanding, and it's understandable. NICE did recommend tirzepatide for NHS use, publishing guidance (TA1026) in December 2024. The crucial detail people miss is that the recommendation comes with a phased rollout tied to strict eligibility cohorts, not an immediate open offer to everyone with obesity.

NICE approval and NHS availability are two different things. The former says the medicine is clinically and cost-effective; the latter depends on which cohort the NHS has activated, whether your GP practice has opted in, and whether local commissioning has caught up. Right now, those three conditions rarely align for anyone below the very highest threshold.

The question of whether your GP specifically can prescribe it has an extra layer: from 1 April 2026 GP practices may prescribe tirzepatide under the new QOF contract terms, but participation is optional. Some practices are doing it; many are not yet resourced to. If you want to understand whether your doctor is likely to prescribe Mounjaro, our overview covers the key factors that influence that decision, which is worth reading before you book an appointment. Worth checking with your surgery directly rather than assuming either way.

Who actually meets the NHS Mounjaro criteria right now

NHS England's phased cohort structure is the key document here. The first cohort, active from June 2025, requires a BMI of 40 or above, plus four or more of five defined weight-related conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That is a very high bar. Most people who want access to Mounjaro do not have four of those five conditions simultaneously.

The second cohort activated on 23 June 2026, extending eligibility to people with a BMI between 35 and 39.9 who still meet the four-or-more-conditions threshold. A further expansion is expected around March 2027, dropping to three conditions at BMI 40 and above. Lower BMI thresholds apply for some ethnic backgrounds, South Asian, Chinese, Middle Eastern, Black African or African-Caribbean patients qualify at BMI readings 2.5 kg/m² below the stated figures.

Even meeting the numbers does not guarantee access. Every NHS patient must take part in wrap-around dietary and activity support, and local commissioning and practice capacity remain limiting factors. The full detail of current NHS eligibility is set out in NICE TA1026's recommendations chapter.

What happens if the NHS route isn't open to you

If your BMI is below 40, you don't have four concurrent weight-related conditions, or your practice simply isn't prescribing yet, the NHS route is closed for now. That covers the majority of people searching this question today.

The private licensed criteria are different. Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, thresholds that include a much larger proportion of adults. A private prescription still requires a clinical assessment from a qualified prescriber; the difference is that there's no waiting list and no requirement to meet multiple comorbidity criteria at once.

For context on what private treatment costs and what a legitimate price actually includes, our Mounjaro pricing page sets out the figures honestly. And if you're wondering whether you can buy Mounjaro directly from Eli Lilly, our overview explains why that route isn't available and what your actual options are.

One thing worth knowing: the private route through a regulated pharmacy like ours requires identity verification and a clinical review before every order. It is not a shortcut around clinical assessment. It is simply a different route (faster and without a referral requirement) that leads to the same clinical scrutiny. Our prescribers, including those you can read about on the clinical team page, review every consultation personally before any treatment is approved.

The private route: what clinical review actually looks like

Mounjaro is a prescription-only medicine. That status doesn't change depending on where the prescription originates, NHS or private, the law is the same. A clinician reviews your health history, current medicines, BMI, and any relevant conditions. There are no guarantees of approval, and nor should there be; the prescriber's job is to make a genuine clinical judgement.

At nume, sorry, at our pharmacy, consultations are free, reviewed the same day by a GPhC-registered Independent Prescriber (not a decision algorithm), and if approved, treatment is dispatched for next-working-day delivery by DPD in plain packaging. Order before 12pm on a weekday and it typically arrives the following morning, useful if you were hoping to start treatment before the week runs away from you.

If you're still weighing up your options, our weight-loss treatment overview explains how different medicines compare, and our FAQ section answers the questions our prescribers hear most often. For anything specific, our support team is available seven days a week.

If you'd like a clinical team to assess whether you're suitable for private treatment, start your free consultation and we'll review your details the same day.